
It was a letdown for Diamyd Medical, which is based in Stockholm, when the the US Food and Drug Administration (FDA) last month placed the company's phase III trial under a "partial clinical hold." The FDA said it couldn't approve all parts of the Swedish company's application to begin the study.
The large phase III trial, named diagnode-3, is planned to take place in the US in addition to a string of European clinics. However, to avoid recruitment timeline shifts due to the US obstacle, Diamyd Medical has accelerated its plans in Europe, having previously planned to begin testing here concurrently with the US trials, or later.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app